The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy

Abstract

Integrins have been reported to mediate cell survival, proliferation, differentiation, and migration programs. For this reason, the past few years have seen an increased interest in the implications of integrin receptors in cancer biology and tumor cell aggression. This review considers the potential role of integrins in cancer and also addresses why integrins are present attractive targets for drug design. It discusses of the several properties of the integrin-based chemotherapeutic agents currently under consideration clinically and provides an insight into cancer drug development using integrin as a target.

Keywords

integrin cancer disintegrin ligand

Introduction

Integrins are a large family of eukayotic cell-surface receptors that mediate dynamic interaction between cells and extracellular adhesion molecules (Humphries, 2000). The integrins recognize extracellular matrix (ECM) proteins or counter-receptors on adjacent cells. ECM molecules that affect cell adhesion include glycoproteins such as fibronectin (Fn) (Gardner and Hynes, 1985), von Willebrand factor (vWF) (Chow et al. 1992), vitronectin (Vn) (Pytela et al. 1985), thrombospondin (Tsp) (Karczewski et al. 1989), tenascin (Tn) (Joshi et al. 1993), collagen (Coll) (Heino, 2000), laminin (Ln) (Burgeson and Christiano, 1997), osteopontin (Opn) (Green, 2001), and other unidentified molecules. A key finding in the discovery of the integrins was that the well known amino acid sequence Arg-Gly-Asp (RGD) which was initially found in fibronectin, serves as a primary cell recognition motif. Subsequently, the RGD sequence was found in many ECM molecules and, in many cases, was responsible for cell attachment (Karczewski et al. 1989; Joshi et al. 1993; Ruggeri et al. 1983; Davis, 1992; Schnapp et al. 1995; Kimura et al. 1998). The recent crystal structures of the extracellular domains of α_Vβ₃ (Xiong et al. 2001; 2002) have provided new insights into integrin activation and ligand recognition. The interaction of integrins with their ligands is dependent upon signals transduced from the cytoplasmic tails to the extracellular domains (Travis et al. 2003). The binding of integrins to their ligands is critically important to many diverse physiological phenomena, such as attachment, cell proliferation (Miyata et al. 2000; Hollenbeck et al. 2004; Hedin et al. 2004; Zhou et al. 2004), migration (Hirsch et al. 1996; Sakai et al. 1998; Fujiwara et al. 2001; Paulhe et al. 2001). Integrins also contribute to the initiation and/or progression of many diseases including tumor invasion, angiogenesis and metastasis (Tsuji et al. 2004; Takanami et al. 2005; Guo et al. 2005; Enserink et al. 2004; Chung et al. 2004; Felding-Habermann et al. 2002; Gladson et al. 1996; Zheng et al. 1999; Zheng et al. 2000).

Integrin Family

Integrin family have atleast 18 α- and 8 β-subunits that are known to comprise least 24 members (Berman et al. 2000; Parise et al. 2000; Humphries, 2000; Hynes, 2002). Additionally, in a recent survey of human genome, 24 α- and 9 β-subunits have been identified (Venter et al. 2001), which implies 6 novel α- and 1 novel β-subunits. However, their existence is not yet firmly established. Integrins are found in many species, ranging from sponges to mammals (Brower et al. 1997; Gettner et al. 1995).

Cell adhesion requires integrin occupancy. The binding of integrins to their ligands has been intensively studied employing proteolytic fragments and synthetic peptides corresponding to selected regions in Fg, Fn and several other matrix components (Table 1).

Table 1

The integrin family of proteins and their ligands.

β₁
	α₁	Colls, laminins
	α₂	Colls, laminins, chondroadherin
	α₃	Laminins (such as laminin-1, -5, -8, -10, and -11), Fn, thrombospondin, TIMP-2, uPAR, collagen, epiligrin, entactin
	α₄	Fn, VCAM
	α₅	Fn, Fg, uPAR
	α₆	Laminins, merosin (laminin α2 chain), kalinin
	α₇	Laminins, merosin (laminin α2 chain),
	α₈	Fn, vitronectin, Tn-C, osteopontin, and nephronectin
	α₉	angiostatin, Tn-C, osteopontin, and ADAMs, VCAM-1, tTG,
	α₁₀	Colls
	α₁₁	Colls
	α_V	Fn, vitronectin
β₂
	α_L	ICAM-1, -2 and -3
	α_M	Fg, ICAMs, iC3b, factor-Xa, denatured ovalbumin
	α_X	Fg, iC3b
	α_D	VCAM, ICAMs
β₃
	α_IIb	Coll, Fn, vitronectin, Fg, vWF, thrombospondin
	α_V	Fn, vitronectin, Fg, vWf, thrombospondin, FGF-2, MMP-2 and some ADAM proteins
β₄
	α₆	Laminins
β₅
	α_V	Vitronectin, uPAR
β₆
	α_V	Fn, Tn
β₇
	α₄	Fn, VCAM, MAdCAM
	α_E	E-cadherin
	α_V	Colls, laminins, Fn
β_N
	α_V	Fn, Colls
β₈
	α_V	Vitronectin, Fn

The various heterodimeric combinations of α and β subunits. Abbreviations used are: Colls: collagens; Fn: fibronectin; TIMP-2: tissue inhibitor of metalloproteinase; uPAR: urokinase-type plasminogen activator (uPA) receptor; VCAM: vascular cell adhesion molecule; Fg: fibrinogen; Tn-c: tenacin-C; ADAMs: a disintegrin and metalloproteinase proteins; tTG: tissue-type transglutaminase; iC3b: inactivated complement component 3b; ICAM: intercellular cell adhesion molecule; vWf: von Willebrand factor; FGF-2: fibroblast growth factor 2; MMP: matrix metallo-proteinases and MAdCAM: mucosal addressin cell adhesion molecule.

As shown in Table 1, the two distinct subunits form noncovalent heterodimers where each subunit has a large extracellular domain (700–100 residues), a single transmembrane domain and a short cytoplasmic domain (20–70 residues). The exception to this is the β₄ subunit which has an extended cytoplasmic domain containing four Fn type III-like domains (Colombatti et al. 1993). All integrin dimers are dissociated by ionic detergents, indicating that the subunits are noncovalently held together.

The α subunits are subdivided into two groups based on some structural differences. The first group is comprised of the α₁, α₂, α_D, α_E, α_L, α_M or α_X subunits, respectively. The second group is composed of α₃, α₄, α₅, α₆, α₇, α₈, α₉, α₁₀, α₁₁, α_IIb or α_V subunits, respectively, and is bridged by a disulphide bond with an exceptional α₄ subunit subjected to a post translational cleavage at a site close to the transmembrane domain of the precursor. Thus, there are two chains linked by a disulphide bridge, a light chain and a heavy chain. The light chain is composed of the cytoplasmic domain, the transmembrane region and a part of the extracellular domain (about 25 kD), while the heavy chain contains the rest of the extracellular domain (about 120 kD). Integrin α₄ is unique among all known integrin α subunit sequences in that it (i) has neither an inserted I-domain, nor a disulfidelinked C-terminal fragment, and (ii) a potential protease cleavage site, near the middle of the extracellular portion of the polypeptide rather than close to the transmembrane domain of other integrin α subunits (Xiong et al. 2001, 2002).

The β₁ integrins generally mediate interaction between cells and ECM (Perlino et al. 2000). The β₂ integrins subfamily including α_Lβ₂, α_Mβ₂, α_Xβ₂, α_Dβ₂, are immunologically restricted to leukocytes and typically have other cell surface molecules as their ligands, for example, α_Lβ₂ interacts with counter receptors ICAM-1, ICAM-2, and ICAM-3 (Marlin and Springer, 1987; de Fouerolles and Springer, 1992; Binnerts et al. 1996; Woska et al. 1996) while α_Mβ₂ recognizes iC3b (Wright and Silverstein, 1983), fibrinogen (Zhang and Plow, 1996) and neutrophil inhibitory factor (NIF) (Muchowski et al. 1994). There are two integrins α_IIbβ₃ and α_Vβ₃ in integrin family, that share the common β₃ subunit, have been reported to function as promiscuous receptors for the RGD-containing adhesive proteins such as fibrinogen, vitronectin, fibronectin, von Willebrand factor, and thrombospondin (Scarborough et al. 1999). The β₄ integrin facilitates key functions of carcinoma cells, including their ability to migrate, invade, and evade apoptosis (Folgiero et al. 2007). The β₅, β₆, β₇, β₈ and β_N subunits can form a dimmer with an α_V subunit binding to different ligands (Table 1) and showing different functions.

Integrin Structure

The first three-dimensional structure of the extracellular domain of an integrin was published in October 2001, a decade and a half after the family was first defined (Xiong et al. 2001, 2002, 2004) (Fig. 1).

Figure 1

Structure of the extracellular segment of α_Vβ₃ derived with permission from Xiong et al. 2002. (A) Bent conformation of α_Vβ₃ as it was present in the crystal. (B) Extension of the structure to reveal its domains.

Crystal structure of integrin α_Vβ₃ showing the dimer and individual subunits (Xiong et al. 2002). An unliganded ectodomain from the αA-lacking integrin α_Vβ₃ contains the two subunts assembled into a globular head built by two predicted domains: the N-terminal seven-bladed propeller domain of α_V and an αA-like domain (βA) from the β₃. βA loops out from the “Hybrid” domain (β₃ residues 55–108 and 353–432), which itself is inserted in the N-terminal plexin/semaphorin/integrin (PSI) domain (residues 1–54 and residues 433–435) of β₃. The PSI domain and the beta-tail domain (βTD), together forming the β₃ leg. Ig-like thigh domain and calf-1 and calf-2 domains formed the α_V leg. Two legs are bent at the “knees” and folded back against the head of the same molecule. This sharp bending takes place between the thigh and calf-1 of α_V (α-genu) and approximately corresponding to between EGF domains 1 and 2 of β₃ (β-genu). A metal ion (Ca²⁺ or Mn²⁺) occupies the α-genu on both the ligand and unliganded structures. At the base of propeller, blades 4–7 each contain a metal ion coordinated in a β-hairpin loop.

Integrin and Cancer

Cancer occurs when cells become abnormal and keep dividing and forming more cells without control or order. If cells keep dividing when new cells are not needed, a mass undifferentiated tissue forms. This mass of extra tissue, called a growth or tumour, can constitute either a benign or a malignant tumour respectively. Benign tumors can usually be removed and, in most cases, they do not come back. Most importantly, cells from benign tumors do not spread to other parts of the body. Benign tumors are rarely a threat to life. In contrast, malignant tumours are truly cancerous. Cancer cells can invade and damage nearby tissues and organs. Cancer cells can break away from a malignant tumor and enter the bloodstream or the lymphatic system. The spread of cancer is called metastasis which appears to be a complex multi-step process that involves the invasion of cancer cells from primary neoplasm followed by their dissemination through the lymphatic vessels and systemic circulation. New blood vessels form either by vasculogenesis, which refers to initial events of vascular growth in which endothelial cell precursors (angioblasts) differentiate and assemble into primitive vessels or by angiogenesis, which refers to a combination of sprouting of new vessels from pre-existing ones, and longitudinal separation of pre-existing vessels in a process named intussusception (Conway et al. 1993). The angiogenesis can be triggered in pathological conditions such as tumor growth and chronic wounding. Angiogenetic process involves functional cooperativity between cytokines and endothelial cell (EC) surface integrins. Cell bound integrins by their physical interaction with ligands necessary are essential for cell adhesion, migration and positioning, and induce signaling events essential for cell survival, proliferation and differentiation. They also trigger a variety of signal transduction pathways which are involved in mediating invasion, metastasis and squamous-cell carcinoma which can be reviewed as follows. The review focuses mainly on specific α and β subtypes which have been most extensively investigated in cancer.

β₁ class of integrins

Although little clear correlation between tumor formation, invasion and β₁ integrin expression has yet been demonstrated in human patients, it has been possible to show a crucial role of β₁ integrin in tumor formation and metastasis in mice. Tumor cells expressing β₁ integrin formed significantly larger primary tumors and had a dramatically increased metastasis into liver and lung (Brakebusch et al. 1999). In another study, which used a T cell lymphoma line in which both β₁ integrin alleles was deleted by homologous recombination, metastasis formation in mice was significantly reduced (Stroeken et al. 2000). Recently, it was shown that ablation of the β₁ integrin gene in mammary epithelium dramatically impaired mammary tumorigenesis in mice (White et al. 2004). Sudhakar et al. have reported that human collagen α1(IV)NC1 binds to α₁β₁ integrin, competes with type IV collagen binding to α₁β₁ integrin, and inhibits migration, proliferation, and tube formation by ECs, indicating that α1 (IV)NC1 is a potential therapeutic candidate for targeting tumor angiogenesis (Sudhakar et al. 2005). A study using β₁ integrin double knockout lymphocytes and retransfection of β₁ integrin deletion mutants have shown that different parts of the cytoplasmic domain of β₁ integrin are required either for adhesion or for invasion and metastasis (Stroeken et al. 2000).

Integrin α₁β₁ and α₂β₁ were shown to regulate hepatocarcinoma cell invasion across the fibrotic matrix microenvironment (Yang et al. 2003). A potent selective inhibitor of α₁β₁ integrin, obtustatin purified from the venom of the Vipera lebetina obtusa viper was reported to have a marked ability to inhibit angiogenesis in vivo in the chicken chorioallantoic membrane assay, and in the Lewis lung syngeneic mouse model (Marcinkiewicz et al. 2003). Grzesiak and Bouvet have demonstrated that the certain cancer cell lines including CFPAC (a ductal epithelioid cell line established from a cystic fibrosis patient with pancreatic adenocarcinoma), BxPC-3 (human pancreas adenocarcinoma), Colo-357 (human lymph node metastasis), and Panc-1 (Pancreatic Cancer Cell Line) attach to 3D type I collagen scaffolds in an α₂β₁-specific manner and that this integrin-specific adhesion is required for subsequent cell proliferation. Such evidences support the notion that targeting α₂β₁ integrin-specific type I collagen adhesion may have therapeutic value in the treatment of pancreatic cancer (Grzesiak and Bouvet, 2007). Integrin α₂β₁ was also reported to mediate the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumour-associated protein which is capable of binding to both α₂β₁ and type I collagen. This protein promoted α₂β₁-dependent cell adhesion and inhibited tumor growth and angiogenesis (Sabherwal et al. 2006). Combined antagonism of α₁β₁ and α₂β₁ was shown to reduce tumor growth substantially as well as angiogenesis of human squamous cell carcinoma xenografts (Senger et al. 2002).

The interaction of α₃β₁ with ligand laminin-5 has been demonstrated to promote the migration and invasion of malignant glioma and melanoma cells (Tsuji, 2004; Tsuji et al. 2002; Giannelli et al. 2007) and to promote binding to virus glycoprotein. A significant increase in proliferation and adhesion in response to collagen 1 and laminin for integrin receptor α₃β₁ was also observed in ovarian cancer cell lines (Ahmed et al. 2005). More recently, uPAR (urokinase-type plasminogen activator receptor), and TIMP (tissue inhibitors of metalloproteinases)-2 were also proposed as ligands of α₃β₁ integrin in mediating uPA/uPAR interaction and intracellular signaling (Wei et al. 2007). In an animal model it was shown that soluble uPAR antagonizes cancer progression (Jo et al. 2003).

The Src family kinases are classified as oncogenic proteins due to their ability to activate cell migration (Rodier et al. 1995; Rahimi et al. 1998) in many cell types including epithelial tumor cells. Studies with chimeric α₄ integrin subunits have shown that α₄ cytoplasmic domain can enhances cell migration via c-Src activation (Chan et al. 1992; Hsia et al. 2005).

α₅β₁ integrin interacts with Fn which is implicated in several cellular activities including cell proliferation, differentiation, and migration. A high-affinity interaction that occurs with the central cell binding domain, a region involved in many fundamental aspects of cell growth and morphogenesis, is dependent on the RGD sequence and other recognition sequences (Li et al. 2003; Murillo et al. 2004). The interaction with Fn has been demonstrated with both lung epithelial cells and fibroblasts. In addition, the inhibition of cell surface α₅ integrin expression was found to decrease phosphoinositide-3 kinase (PI3K) activity and inhibit colon cancer cell attachment, suggesting that agents which selectively target α₅ integrin subunit expression may enhance the effects of standard chemotherapeutic agents and provide a novel adjuvant treatment for selected colon cancers (Lopez-Conejo et al. 2002). Furthermore, cells expressing the α₅β₁ integrin displayed a dramatic enhancement in the ability of growth factors to activate PI3K and protein kinase B (PKB), indicating this stimulation may also involve the interaction between α₅β₁ and the PI3 K and PKB signalling pathways (Lee et al. 2000). Wei et al. recently reported that urokinase receptor binding to α₅β₁ is required for maximal responses to Fn and tumor cell invasion (Wei et al. 2007). Kuwada et al. demonstrated that expression of integrin α5β1 in colon cancer cells decreases HER (human epidermal growth factor receptor)-2-mediated proliferation, crystal violet assays were showing inhibition of the cell proliferation of Caco-2 control cells with the antagonistic HER-2 antibody mAb 4D5 (Kuwada et al. 2005). MAb 4D5 is also indicated clinically active in cancer patients to target HER2-overexpression (Baselga et al. 1996; Rhodes, 2005). Furthermore, mAb 4D5 has been shown great promise as targeted agents in the treatment of patients with cancer (Bartsch et al. 2007).

It has been reported that α₆ integrin-mediated neutrophil migration through the perivascular basement membrane (PBM) is platelet-endothelial cell adhesion molecule1 (PECAM-1) dependent, a response associated with PECAM-1-mediated increased expression of α₆β₁ on transmigrating neutrophils (Dangerfield et al. 2002). Significantly increased ovarian cancer cell line proliferation and adhesion to collagen 1 and laminin (ligands of integrin receptor α₆β₁) were also reported (Ahmed et al. 2005). In addition, an α₆ integrin is found to be overexpressed in human oesophageal carcinomas, suggesting an important role in oesophageal tumor invasion (Tanaka et al. 2000). This notion has since been confirmed by other studies (Mercurio et al. 2001; Demetriou et al. 2004).

The α₇β₁ integrin is a laminin-binding receptor that was originally identified in melanoma (Kramer et al. 1991). Ziober et al. reported that during melanoma progression, acquisition of a highly tumorigenic and metastatic melanoma phenotype is associated with loss of the α₇β₁ (Ziober et al. 1999). Integrin α₇β₁ serves an important mechanical function in the diaphragm by contributing to passive compliance, viscoelasticity, and modulation of muscle contractile properties (Lopez et al. 2005).

Integrin α₁₀β₁ is a major collagen-binding integrin during cartilage development and in mature hyaline cartilage while α₁₁β₁ was originally found in fetal muscle (Gullberg et al. 1995). Integrin α₁₁β₁ recognizes the triple-helical GFOGER sequence (where single letter amino acid nomenclature is used, O = hydroxyproline) found in interstitial collagens (Tulla et al. 2001). Little is known about the biology of these recently identified integrins. Integrin α₁₀β₁ is expressed on chondrocytes and some fibrous tissues. Integrin α₁₁β₁ is involved in cell migration and collagen reorganization in mesenchymal non-muscle cells (Tiger et al. 2001). Recently, α₁₁β₁ integrin is required on periodontal ligament fibroblasts for cell migration and collagen reorganization by assisting axial tooth movement (Popova et al. 2007).

α_V class of integrin

The first integrin found associated with tumor angiogenesis was α_Vβ₃ (Eliceiri et al. 1998; Eliceiri, 2001; Ruegg et al. 2003). Integrin α_Vβ₃ has a broad distribution and is found on endothelial cells, smooth muscle cells (SMCs) and hematopoietic cell types such as platelets and osteoclasts. The interaction of α_Vβ₃ with its ligands plays a crucial role in angiogenesis and neointimal formation after vascular injury. In addition, during osteoclast-mediated bone resorption, α_Vβ₃ regulates the cytoskeletal organization required for cell migration and formation of the sealing zone (McHugh et al. 2000). Prostate cancer specific integrin α_Vβ₃ was demonstrated to modulate bone metastatic growth and tissue remodeling (McCabe et al. 2007). The study of co-expression of bone sialoprotein, integrin α_Vβ₃, and MMP-2 in papillary thyroid carcinoma cells demonstrated that cancer cells appear to become more invasive when bone sialoprotein forms a cell-surface trimolecular complex that links MMP-2 to integrin α_Vβ₃ (Karadag et al. 2004). Bayless et al. present very convincing data showing that integrin α_Vβ₃ as well as integrin α₅β₁ regulate human endothelial cell vacuolation and lumen formation, implicating a major role contributed by these two integrins for endothelial cell morphogenesis (Bayless et al. 2000). It is also clear that the integrin α_Vβ₃ plays an important role in virtually every stage of cancer progression. Indeed, neuroblastoma aggressiveness has been identified to be correlated with the expression of integrin α_Vβ₃ and α_Vβ₅ by microvascular endothelium (Erdreich-Epstein et al. 2000). Other studies also demonstrate that increased α_Vβ₃ expression level is closely associated with increased cell invasion and metastasis (Feldin-Habermann et al. 2002). Li et al. reported that antisense α_V suppressed tumour growth more strongly than antisense β₃, antisense therapy but simultaneous targeting at both integrin subunits was more effective than the respective mono-therapies (Li et al. 2007). Integrin α_Vβ₃ has been demonstrated to interact with the activated forms of the platelet-derived growth factor, insulin, and vascular endothelial growth factor (VEGF) cell receptors faciliting optimal activation of cell proliferative signalling pathways (Giancotti and Ruoslahti, 1999; Kumar, 2003). The functional activity of αvβ3 on endothelial and tumor cells may well be regulated by VEGF (Byzova et al. 2000). VEGF has been also implicated in prostate carcinogenesis and metastasis as well as in angiogenesis. Both VEGF and its receptor are expressed by prostate carcinoma cells at a high level (Ferrer et al. 1998; 1999).

A role for α_Vβ₆-mediated production in the regulation of MMP-9 and MMP-3 have been reported in several tumor types and in untransformed keratinocytes (Ramos et al. 2002; Ahmed et al. 2002). MMP-9 plays a critical role in the recruitment of bone marrow derived CD45 positive cells into the primary tumor and the establishment of a mature vasculature (Jodele et al. 2005). Integrin α_Vβ₆ also plays a role in wound healing and cancer of the oral cavity (Thomas et al. 2006). In addition, α_Vβ₆ has been implicated in the regulatory control of the uPA proteolytic cascade (Ahmed et al. 2002). A gradual increase in the expression of α_Vβ₆ integrin from borderline to malignant tumors has been reported in oral squamous carcinomas (Jones et al. 1997) and breast carcinomas (Arihiro et al. 2000). In malignant keratinocytes and colon cancer cells, increased expression of this integrin enhances MMP-9 secretion and MMP-9-mediated invasion (Thomas et al. 2000; Agrez et al. 1999). Inhibition of α_Vβ₆ function using inhibitory antibodies results in total abrogation of MMP-9 activation (Thomas et al. 2001) suggesting that the expressions of α_Vβ₆ integrin and MMP-9 are linked, and their coordinate expression appears to promote invasion by squamous and colon carcinoma cells. The integrin α_Vβ₆ interacts with Fn, Vn (Huang et al. 1998), tenascin (Weinacker et al. 1995), and latency-associated peptide (Munger et al. 1999), a protein derived from the N-terminal region of the transforming growth factor(TGF)-β gene product that mediates cell adhesion, spreading, migration, proliferation, and activation of latent TGF-β (Weinreb et al. 2004; Thomas et al. 2001).

Until recently, there has been little information about integrin α_Vβ₈ which has been reported to function as an additional receptor for foot-and-mouth disease virus (FMDV) (Jackson et al. 2004) in addition to the three RGD-dependent integrins α_Vβ₁, α_Vβ₃, and α_Vβ₆, which have been shown to be receptors for FMDV previously (Jackson et al. 1997, 2000, 2002; Duque et al. 2004). Notably, α_Vβ₈ as well as α_Vβ₆ may promote epithelial-mesenchymal transition (EMT) by contributing to the activation of TGF-β (Munger et al. 1999). Additionally, α_Vβ₈–-mediated activation of TGF-β was shown to block the proliferation of certain cancer cells (Mu et al. 2002). Several recent studies have demonstrated that both up-regulation and down-regulation of expression of α_V integrins and other integrins can be effective markers of malignant diseases and patient prognosis.

Although there are few reports of enhanced expression of α_IIbβ₃ (than of α_Vβ₃₎ integrin in tumour cells, one observation indicated an important role in tumour progression. A study on human melanoma biopsies showed that α_IIbβ₃ expression increased with tumour thickness (Trikha et al. 2002a). In addition, a single pretreatment of human melanoma cells with c7E3 Fab, an α_IIbβ₃ antibody inhibited lung colonization of the tumor cells in severe combined immunodeficient mice (Trikha et al. 2002b).

Other sub-classes of integrins

Parathyroid hormone-related protein (PTHrP) was reported to not only increase transcriptional activity of the integrin subunit α₅ (Anderson et al. 2007) but also upregulate integrin α₆β₄ expression and activate Akt in breast cancer cells (Dittmer et al. 2006; Shen and Falzon, 2006; Shen et al. 2007). Falcioni et al. first identified a tumor antigen (TSP-180) associated with metastasis that was shown to be identical to the β₄ integrin subunit (Falcioni et al. 1997; Kennel et al. 1989). Subsequently other studies showed that expression of α₆β₄ persists in some aggressive carcinomas and that its expression may be linked to the behavior of these tumors (Guo et al. 2004). At earlier of the year in 2001, Davis and his colleagues demonstrated that α₆β₄ integrin has an influence on tumour biology as this integrin and its ligand, laminin-5, are essential gene products for the maintenance and remodeling of a stratified epithelium (Davis et al. 2001). The β₄ integrin, for example, was lost in the lesions of prostatic intraepithelial neoplasia together with basal cell-lining and in prostate carcinoma the expression of β₄ integrins was totally lost (Davis et al. 2001). In normal skin keratinocytes, expression of the α₆β₄ integrin is restricted to the proliferative basal layer and mediates stable adhesion to the underlying basement membrane. Observations in carcinoma cells show a functional and spatial dissociation of the α₆β₄ integrin from the hemidesmosomal complex, which stimulates cell migration and, therefore, may contribute to carcinoma invasion (Kippenberger et al. 2004). Indeed, many carcinomas express elevated levels of α₆β₄ (Herold-Mende et al. 2001), particularly breast carcinomas (Chung and Mercurio, 2004).

Pawar et al. recently have shown that the uPA-mediated cell surface cleavage of the alpha6 integrin extracellular domain is involved in tumor cell invasion and migration on laminin (Pawar et al. 2007). In addition, observations in carcinoma cells show a functional and spatial dissociation of the α₆β₄ integrin from the hemidesmosomal complex, which stimulates cell migration (Kippenberger et al. 2004). Furthermore, blocking antibodies to either α₆ or β₄ integrin subunits suppress the formation of apoptosis-resistant acinar structures in Matrigel by mammary epithelial cells (Weaver et al. 2002), suggesting a role for β₄-mediated cellular polarity in mediating antiapoptotic signaling. Integrin α₆β₄ was recently noted only at the cell's basal interface with the basement membrane in normal pancreatic ducts. But in pancreatic adenocarcinomas, 92% demonstrated overexpression of integrin α₆β₄ and altered localization to the cytoplasm and membranous regions, this upregulation and redistribution of integrin α₆β₄ expression implicated a role of integrin in pancreatic adenocarcinoma progression (Cruz-Monserrate et al. 2007). Interestingly, the expression of β₄ was inversely correlated with dissemination of ten human gastric cancer cell lines in SCID (severe combined immunodeficiency) mice (Ishii et al. 2000). In addition, strong evidence suggests that reduced expression of α₆ and β₄ subunits may contribute to the higher tumorigenicity of androgen-independent prostate tumor cells (Bonaccorsi et al. 2000).

Several key signalling molecules in carcinoma cells are also involved in the mechanisms of α₆β₄ integrin-mediated tumour behaviour (Bon et al. 2007; Folgiero et al. 2007) since β₄ has been demonstrated to interact with ERBB2 (erythroblastic leukemia viral oncogene homolog 2, encoding an 185-kDa, 1255 amino acids, orphan receptor tyrosine kinase) that displays potent oncogenic activity when overexpressed) in some cultured breast tumour cells, and the two proteins synergize in promoting cellular proliferation and invasion (Falcioni et al. 1997). In addition, Guo et al. established that integrin α₆β₄ may be required for mammary tumourigenesis driven by the expression of ErBB2 (Guo et al. 2006). Folgiero et al. revealed that α₆β₄ can regulate the expression of ErBB-3 at the level of protein translation, resulting in a significant induction of ErBB-2/ErBB-3 heterodimerization and consequent activation of PI3K (Folgiero et al. 2007; Liu et al. 2007). Introduction of β₄ in β₄-negative breast carcinoma cells activates signalling from PI3K to Rac (a member of the Rho family of small guanosine triphosphatases) and increases the invasion of these cells in vitro (Shaw, 2001).

The integrin α_Eβ₇ (also known as cell marker CD103) is expressed by most intra-epithelial lymphocytes (IEL). An important ligand for this molecule is the epithelial cell adhesion molecule E-cadherin. Cresswell et al. have demonstrated that the up-regulation of integrin α_Eβ₇ by lymphocytes increases adhesion to E-cadherin expressing bladder cancer targets, indicating a role of integrin α_Eβ₇ in cancer invasion (Cresswell et al. 2002).

Integrins as Targets for the Treatment of Cancer

From what has been discussed above, integrins play a key role in tumor angiogenesis and cancer. Because they are cell surface receptors interacting with extracellular ligands, they represent ideal pharmacological targets. A variety of integrin antagonists such as low molecular weight inhibitors, peptidomimetics, or monoclonal antibodies are in various stages of development as anti-cancer therapeutics (Kerr et al. 2002; Mousa 2002; Tucker et al. 2003).

In-vivo study has demonstrated that the addition of inhibitory anti-β₁-integrin antibodies or the re-expression of α₂β₁ integrins leads to the reversal of the malignant phenotype in a 3-dimensional cell culture model and to a reduction in tumour formation in animal models (Zutter et al. 1995). Yao et al. recently show that β₁ integrin expression has potential prognostic value in invasive breast cancer and that coexpression of fibronectin may help identify patients with more aggressive tumors who may benefit from targeted therapy (Yao et al. 2007). More studies have been focused on α_Vβ₃, since α_Vβ₃ has been identified as a prognostic indicator of survival and a specific potential target for control of angiogenesis, therapies directed against integrin against α_Vβ₃, have been developed (Brooks et al. 1994; Gladson et al. 1996; Zhang et al. 2007; Gramoun et al. 2007).

Antibodies against Integrins as Inhibitors

MEDI-552

Brooks and his coworkers first showed that a monoclonal antibody specific for α_Vβ₃, MEDI-552 (LM609), could block angiogenesis in a murine model (Brooks et al. 1994). In addition, there is an ongoing phase I dose escalation study evaluating the safety of MEDI-522 in patients with advanced malignancies. This antibody was chosen for its unique ability to selectively target multiple and different cell types. In a phase I trial on various solid tumours, MEDI-522 appeared to be without significant toxicity (McNeel et al. 2005). MEDI-522 was detectable both in quiescent and in angiogenically active skin blood vessels as well as in the dermal interstitial space. The levels of phosphorylated focal adhesion kinase (pFAK) were reduced during MEDI-522 treatment, suggesting a modulating effect on this signaling molecule (Zhang et al. 2007; Gramoun et al. 2007).

CNTO 95

A fully humanized monoclonal antibody to anti-α_V integrins, CNTO 95, has been shown to inhibit angiogenesis and tumor growth in preclinical studies (Mullamitha et al. 2007). CNTO 95 is likely to be less immunogenic in humans compared to chimeric or humanized antibodies (Trikha et al. 2004). CNTO 95 bound to purified α_Vβ₃ and α_Vβ₅ with higher affinity (a Kd of approximately 200 pM and to α_V integrin-expressing human cells with a Kd of 1–24 nM). In vitro, CNTO 95 potentially inhibited human melanoma cell adhesion, migration and invasion (doses ranging 7–20 nM) and appeared to be safe without inhibition of normal physiologic angiogenesis (Martin et al. 2005; Trikha et al. 2004).

17E6

The 17E6 antibody strongly perturbs cell attachment mediated by α_V associated integrins, by reacting with α_Vβ₃, α_Vβ₅, and α_Vβ₁, and has the ability to disrupt stable interaction between vitronectin and α_Vβ₃, and blocks the growth of M21 tumours in nude mice. In two nude mouse tumor models, injection of 17E6 strongly inhibited tumor development (Mitjans et al. 2000; Mitjans et al. 1995).

Integrin antibodies that block specific integrins for treatment of cancer are still in clinical trial stages as lessons should be learnt from integrin antibodies for the treatment of other diseases. For example, Tysabri (also called natalizumab), an antibody which blocks α₄ integrins and inhbits the α₄-mediated adhesion of leukocytes to their counterreceptor (s) (Minagar et al. 2000; O'Connor et al. 2004, 2005). Although the specific mechanism(s) by which tysabri exerts its effects in multiple sclerosis (MS) have not been fully characterized, Tysabri was initially approved by the Food and Drug Administration (FDA) in U.S.A. in November, 2004 for the treatment of patients with relapsing forms of MS, but was withdrawn by the manufacturer three months later after three patients developed progressive multifocal leukoencephalopathy (PML), a serious viral infection of the brain, in the drug's clinical trials, FDA then put clinical trials of the drug on hold, allowing them to resume a year later after confirming that there were no additional cases of PML. In June 2006, the FDA resumed marketing of Tysabri with a restricted distribution program. Tysabri is indicated for use as monotherapy, because we do not know enough about how its use with other immune modifying drugs could impact risk. (www.fda.gov/cder/drug/infopage/natalizumab).

Other antibodies

α₁β₁ and α₂β₁ integrins play a significant role in the VEGF-driven angiogenesis. Ha 31/8 and Ha 1/29 are antibodies against α₁ and α₂ integrin subunits which were reported to inhibit endothelial cells in a gradient of immobilized collagen I assay (haptotaxis) by <40%, whereas the combination of both antibodies synergized to reach <90% inhibition (Alghisi and Ruegg, 2006). Consistent with these results, administration of both the anti-α₁ and the anti-α₂ antibodies to nude mice bearing a human A431 squamous cell carcinoma xenograft suppressed angiogenesis by <60% and tumor growth by >40% (Senger et al. 2002). Interestingly, preclinical studies with monoclonal antibodies (MAbs) against lactadherin, a glycoprotein of the milk fat globule membrane was found that there was a clear increase in VEGF-like proangiogenic activity (Taylor et al. 1997; Silvestre et al. 2005) when lactadherin is added back exogenously to the ischemic muscles. An investigation has further identified lactadherin as a physiological ligand of α_Vβ₃ and α_Vβ₅, thus confirming a proangiogenic activity of these integrins in the VEGF-dependent neovascularization in adult mice, but not in embryos. Animal test showed that the expression of Flk-1 (VEGFR-2) is elevated in β₃-deficient mice, indicating that α_Vβ₃ can control the amplitude of the VEGF response by controlling the Flk-1 level or activity (Reynolds et al. 2004). In vitro, anti-α₅β₁ function-blocking mAbs (NKI-SAM-1, JBS5, or IIA1) inhibited adhesion in a 72% to 100% range depending on the cell line used. This result was further confirmed in vivo in an angiogenesis assay treated with fibroblast growth factor 2 (Kim et al. 2000). The anti-α₅β₁ M200 antibody (Volociximab) is another chimeric monoclonal antibody of α₅β₁ integrin that blocks tumor growth and metastasis. M200 binds to α₅β₁ integrin on activated endothelial cells with high binding affinity and inhibits in vitro tube formation induced by VEGF and/or bFGF, suggesting a mechanism of action independent of growth factor stimulus. In fact, inhibition of α₅β₁ function by M200 induced apoptosis of actively proliferating, but not resting endothelial cells (Ramakrishnan et al. 2006).

Disintegrins, RGD-Based Peptides and Small Molecule Integrin Antagonists

The “disintegrin” terminology was initially applied in 1990 to describe a family of cysteine-rich, RGD-containing proteins from viper venom toxins that inhibit platelet aggregation and integrin-mediated cell adhesion (Gould et al. 1990; Niewiarowski et al. 1994; McLane et al. 2004). Studies of RGD-containing proteins in venom toxins have been found that a number of them, such as contortrostatin, salmosin and bitistatin (Markland et al. 2001; Zhou et al. 1999; Swenson et al. 2004; Golubkov et al. 2003; Kang et al. 1999; Chung et al. 2003; McQuade et al. 2004), are able to inhibit tumor growth and angiogenesis. Echistatin has been found to induce a decrease of both autophosphorylation and kinase activity of pp125FAK, suggesting inhibitory activity in processes integral to angiogenesis, such as cell growth, survival, and migration (Della et al. 2000). Triflavin was found to interact with either α_IIbβ₃ on platelet membranes, resulting in inhibition of platelet adhesion, secretion, and aggregation in injured arteries, or α_Vβ₃ on SMCs subsequently inhibiting cell migration and proliferation (Sheu et al. 2001). Triflavin also blocks neuronal sprouting and the induction of hyperalgesia induced by peripheral nerve injury (Fu et al. 2004). Recently, soluble RGD peptides have been demonstrated to induce apoptosis by inducing conformational changes in procaspases, leading to increased oligomerization and subsequent autoprocessing of these enzymes (Buckley et al. 1999). In addition, RGD-containing proteins from venom toxins (e.g. salmosin, contortrostatin, rhodostomin and accutin) were also found to induce apoptosis (Chung et al. 2003; Zhou et al. 1999; Wu et al. 2003; Yeh et al. 1998). It is still not clear whether these proteins’ apoptotic induction is through interaction with integrins or through a different apoptotic pathway since Jan et al. in a recent issue of Cell have shown that integrins may regulate apoptosis, through caspase-independent mechanisms (Jan et al. 2004). These data have shown the potential for these RGD-containing snake venom proteins to function as integrin antagonists as well as anti-angiogenic and antimetastatic compounds, leading to drug development for therapeutic usage (Markland et al. 2001; Kerr et al. 2002; Hallahan et al. 2001; Coller, 2001).

The integrins that bind to RGD peptides are generally over-expressed in angiogenic vessels. In certain cancer, the tumor cells also express RGD-binding integrins. A vast body of preclinical and clinical literature exists on the use of RGD-based integrin antagonists in cardiovascular disease and cancer (Tucker, 2003; McQuade and Knight, 2003; Kumar et al. 2003; Shimaoka and Springer, 2004). A cyclic pentapeptide called EMD66203 [cyclic L-Arg-L-Gly-L-Asp-D-Phe-L-Val (RGDfV) peptide or cyclo(-Arg-GlyAsp-D-Phe-Val)](Aumailley et al. 1991) was shown preferential inhibition of vitronectin binding to the α_Vβ₃ rather than to the α_IIbβ₃ (Frieser et al. 1996). Further modification of the EMD66203 led to the synthesis of EMD121974, an RGD-containing pseudopeptide (c(RGDfV)) or cyclo(Arg-Gly-Asp-D-Phe-[NMe]Val) also known as cilengitide (Dechantsreiter et al. 1999). Structural study revealed that the D-amino acid in this peptide is found preferentially in position i + 1 of a β II’ turn, a characteristic for its biological activity. EMD121974 is also a dual α_Vβ₃/α_Vβ₅ integrin antagonist with interesting biochemical and biological features to be tested in cancer therapy (Belvisi et al. 2005, 2006). The crystal structure of the extracellular segment of integrin α_Vβ₃ in complex with EMD121974 revealed that the pentagonal peptide inserted into a crevice between the propeller and βA domains on the integrin head (Xiong et al. 2002). EMD 121974 was demonstrated to be an α_V-integrin antagonist and a potent inhibitor of angiogenesis, by inducing apoptosis of growing endothelial cells through inhibition of their α_V-integrin interaction with the matrix proteins vitronectin and tenascin (Taga et al. 2002).

ST1646, an RGD-containing pseudopeptide, is a potent, highly selective α_Vβ₃/α_Vβ₅ integrin antagonist, equipotent to or more potent than the well-characterized integrin antagonists c(RGDfV) (Belvisi et al. 2006; Haier et al. 2002). The structure docking model for the ST1646-α_Vβ₃ complex has confirmed that, similarly to the crystal structure of the EMD121974-α_Vβ₃ complex, the ligand seems to interact mainly through electrostatic forces in a rather shallow cleft and that essentially no hydrophobic interactions can be observed (Belvisi et al. 2005). In an in vitro anti-angiogenic activity assay, ST1646 inhibited HUVEC proliferation with potency similar to EMD121974 (IC₅₀, 2.9 and 4.4 μmol/L for the two compounds, respectively). The inhibitory effect was reversible. In an in vivo antiangiogenic activity assay as determined by daily administration of ST1646 (30 μg/embryo) with CAM (chick chorioallantoic membrane) assay at day 9 via a gelatin sponge implant and at day 12 for histologic analysis, showed significant inhibition of the angiogenic response triggered by both FGF2 and VEGF (p < 0.001) (Belvisi et al. 2005).

SCH 221153, an RGD-based peptidomimetic, inhibits the binding of the disintegrin, echistatin to α_Vβ₃ and α_Vβ₅ with similar potency, according to IC₅₀ values of 3.2 nM and 1.7 nM, respectively (Kumar et al. 2001). SCH 221153 inhibits FGF2 and VEGF-induced endothelial cell proliferation in vitro according to IC₅₀ equal to 3–10 μM (Kumar et al. 2001). Monsanto-Searle (St. Louis, MO) has reported an orally compound SC-68448 which inhibited α_Vβ₃-mediated endothelial cell proliferation in a dose-dependent manner but did not inhibit tumor cell proliferation, suggesting that effects on endothelial cell proliferation were not due to SC-68448-induced cytotoxicity. SC68448 was 100-fold more potent as a functional inhibitor of α_Vβ₃ versus α_IIbβ₃ (Carron et al. 2000). Integrin α_IIBβ₃ expressed mainly on platelet membrane plays a crucial role in platelet aggregation and thrombus formation, and recently was reported to have a role in increasing the risk of metastases in renal cell carcinoma in men (Kallio et al. 2006). Haubner and his co-workers reported that ¹⁸F-Galacto-RGD is a highly α_Vβ₃-selective tracer for positron emission tomography (PET) (Haubner et al. 2004, 2001). Molecular imaging with ¹⁸F-Galacto-RGD and PET provides important information for planning and monitoring anti-angiogenic therapies targeting the α_Vβ₃ integrin (Beer et al. 2006). Meerovitch et al. demonstrated BCH-14661 and BCH-15046, RGD peptidomimetic compounds are as apoptotic inducers for endothelial cells by causing cell detachment-dependent when cells are grown on RGD-containing integrin ligand vitronectin and fibronectin. BCH-14661 was specific for integrin α_Vβ₃, whereas BCH-15046 nonselectively antagonized α_Vβ₃, α_Vβ₅, and α₅β₁ (Meerovitch et al. 2003). A 20 amino acid N-terminal peptide of angiocidin was reported to promote α₂β₁- dependent adhesion of K562 cells, disrupt human umbilical vein endothelial cell tube formation and inhibit tumour growth as well as angiogenesis in a mouse model (Sabherwal et al. 2006). Angiocidin has also been reported to inhibit angiogenesis through binding collagen and integrin α₂β₁ present on many tumour cells (Sabherwal et al. 2006).

The most selective nonpeptidic α₅β₁ antagonist SJ749 showed a reduced proliferation of astrocytoma cell lines dependent on α₅β₁ expression levels and cell culture conditions, underlining the importance of α₅β₁ as a target for anticancer therapies (Marinelli et al. 2005; Maglott et al. 2006). A non–-peptide RGD mimetic, S36578-2, was also developed and demonstrated as highly selective antagonist of both α_Vβ₃ and α_Vβ₅ integrins that was able to induce detachment, caspase-8 activation, and apoptosis in human umbilical endothelial cells (HUVECs) plated on vitronectin (Maubant et al. 2006). Reinmuth and his co-works demonstrated that S-247, another α_Vβ₃/α_Vβ₅ integrin antagonist, showed significant antimetastatic and antiangiogenic activity and impaired both endothelial and hVSMC/pericyte function in vitro and in vivo (Reinmuth et al. 2003; Harms et al. 2004).

The integrin-induced signaling cascades have also been demonstrated to impact tumor cell survival, cell migration, and angiogenesis. It is known that transforming growth factor (TGF)-beta suppresses breast cancer formation by preventing cell cycle progression in mammary epithelial cells (MECs). During the course of mammary tumorigenesis, genetic and epigenetic changes negate the cytostatic actions of TGF-beta, thus enabling TGF-beta to promote the acquisition and development of metastatic phenotypes. TGF-β stimulation can induce α_Vβ₃ integrin expression in a manner that coincides with epithelial-mesenchymal transition (EMT) in MECs. Introduction of siRNA against β₃ integrin can block TGF-β induction and also prevent TGF-β stimulation of EMT in MECs (Galliher and Schiemann, 2006). Therefore, antagonists of growth factor receptors (Cardones et al. 2006; Wick et al. 2006) can be used for anti-cancer therapy. Indeed, the recognition of potent, sequence-selective gene inhibition by siRNA oligonucleotides and rapid adoption as the tool of choice in cell culture has generated the expectation for their use to improve targeted therapeutics (Elbashir et al. 2002; Paddison et al. 2003; Carpenter and Sabatini, 2004; Ganju and Hall, 2004). The prospects of siRNA to be a therapeutic tool were enhanced by their double-stranded RNA (dsRNA) oligonucleotide nature, resembling antisense, ribozymes and gene therapy (Song et al. 2003; Davidson et al. 2004). Silencing integrin α_V expression by siRNA can inhibit proliferation and induce apoptosis in integrin α_V over-expressing MDA-MB-435 human breast cancer cells (Cao et al. 2006). Lipscomb and his co-workers demonstrated that siRNA oligonucleotides targeted to either subunit of the α₆β₄ integrin reduced cell surface expression of this integrin and resulted in decreased invasion of MDA-MB-231 breast carcinoma cells (Lipscomb et al. 2003). Recently gene transfer of antisense α_V and β₃ expression vectors was demonstrated to downregulate α_V and β₃ in HepG2 tumours established in nude mice, inhibit tumour vascularization and growth, and enhance tumour cell apoptosis, suggesting that antisense gene therapy targeting α_V integrins could be as an approach to treat hepatocellular carcinomas (Li et al. 2007).

A study using SUM-159 breast carcinoma cell line showed that decreased expression of the α₆β₄ integrin led to enhanced apoptosis. Recombinant VEGF is able to significantly inhibit the cell death observed in the β₄-deficient cell line. The specificity of α₆β₄ in both in vitro and in vivo assays showed that reexpression of the β₄ subunit into the β₄-deficient cell line could rescue the functional phenotype (Lipscomb et al. 2005).

Conclusions

In this review the potential roles of integrin in tumor progression and cancer were discussed. Evidence presented here indicates that integrins represent highly appropriate pharmacological targets as based upon the beneficial effect of integrin antibodies and antagonists in cancer treatment. A number of the integrin antibodies and antagonists are now in clinical trials, determining their effect on angiogenesis, metastasis and tumour growth (Table 2).

Table 2

Integrin inhibitors in clinical development as anticancer agents.

Antibodies	Other names	Target integrin	Comments on highest phase reached	Company	References
LM609	Vitaxin, MEDI-552	α_Vβ₃	Currently in Phase II	Scripps Research Institute	Brooks et al. 1994; Gutheil et al. 2000 McNeel et al. 2005
CNTO95		α_Vβ₃, α_Vβ₅	Currently in phase I	Centocor. Medarex	Trikha et al. 2004 Mullamitha et al. 2007
Ha31/8		α₁β₁			Senger et al. 2002
17E6		α_Vβ₃		Merck	Mitjans et al. 1995, 2000
Ha1/29		α₂β₁			Senger et al. 2002
NKI-SAM-1, JBS5		α₅β₁			Francis et al. 2002
M200	Volociximab Eos-200-4	α₅β₁	Currently in phase II	Protein design Labs	Protein Design Labs, www.pdl.com
Peptides
SCH 221153					Kumar et al. 2001
EMD 121974	Cilengitide	α_Vβ₅	Currently in phase II	Merck KGaA, EMD Pharmaceuticals, National cancer Institute	Taga et al. 2002
ST1646		α_Vβ₃			Belvisi et al. 2005
angiocidin		α₂β₁			Sabherwal et al. 2006
¹⁸F-Galacto-RGD					Haubner et al. 2004, 2001
Nonpeptidic
SJ749		α₅β₁			Marinelli et al. 2005; Maglott et al. 2006
E7820		α₂ subunit	Phase I	Eisai Medical Research
S36578-2		α_Vβ₃, α_Vβ₅			Maubant et al. 2006
S-247		α_Vβ₃, α_Vβ₅			Reinmuth et al. 2003; Harms et al. 2004

Footnotes

Biography: Xinjie Lu is a principal investigator of on-going project “Development a DNA-based vaccine against atherosclerosis”. Dr. Xinjie Lu received a D. Phil in Biochemistry in Imperial College in the U.K. in 1995. Since then he worked as a postdoctoral research fellow, a lecturer, a senior lecturer and the head of the Protein Biochemistry section, then the head of Molecular Immunology section at Thrombosis Research Institute in U.K. His principal research interests have been in the protein-protein interaction area on BHF founded projects (BHF Project Grant No. PG/97047, PG/99159 and PG/02/126) since 1977.

References

Ahmed

, Riley

, Rice

G.E.

2002. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem., 50: 1371–80.

Ahmed

, Riley

, Rice

2005. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin. Exp. Metastasis, 22: 391–402.

Agrez

, Gu

, Turton

1999. The alpha v beta 6 integrin induces gelatinase B. secretion in colon cancer cells. Int. J. Cancer, 81: 90–7.

Alghisi

G.C.

, and Ruegg

2006. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium, 13: 113–35.

Anderson

J.A.

, Grabowska

A.M.

, and Watson

S.A.

2007. PTHrP increases transcriptional activity of the integrin subunit alpha(5). Br. J. Cancer, [Epub ahead of print].

Arihiro

, Kaneko

, Fujii

2000. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer, 7: 19–26.

Aumailley

, Gurrath

, Muller

1991. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 291: 50–4.

Bartsch

, Wenzel

, Zielinski

C.C.

2007. HER-2-Positive Breast Cancer: Hope Beyond Trastuzumab. Bio. Drugs, 21: 69–77.

Baselga

, Tripathy

, Mendelsohn

1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER.2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737–44.

10.

Bayless

K.J.

, Salazar

, and Davis

G.E.

2000. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am. J. Pathol, 156: 1673–83.

11.

Beer

A.J.

, Haubner

, Sarbia

2006. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer. Res., 12: 3942–9.

12.

Belvisi

, Riccioni

, Marcellini

2005. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol. Cancer. Ther., 4: 1670–80.

13.

Belvisi

, Bernardi

, Colombo

2006. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg. Med. Chem., 14: 169–80.

14.

Berman

A.E.

, and Kozlova

N.I.

2000. Integrins: structure and functions. Membr. Cell. Biol., 13: 207–44.

15.

Binnerts

M.E.

, van Kooyk

, Edwards

C.P.

1996. Antibodies that selectively inhibit leukocyte function-associated antigen 1 binding to intercellular adhesion molecule-3 recognize a unique epitope within the CD11a I domain. J. Biol. Chem., 271: 9962–8.

16.

Bon

, Folgiero

, Di Carlo

2007. Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res., 9: 203.

17.

Bonaccorsi

, Carloni

, Muratori

2000. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology, 141: 3172–82.

18.

Brakebusch

, Wennerberg

, Krell

H.W.

1999. β1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts. Oncogene, 18: 3852–61.

19.

Brooks

P.C.

, Clark

R.A.

, and Cheresh

D.A.

1994. “Requirement of vascular integrin alpha v beta 3 for angiogenesis” 264: 569–71.

20.

Brower

D.L.

, Brower

S.M.

, and Hayward

D.C.

1997. Molecular evolution of integrins: genes encoding integrin beta subunits from a coral and a sponge. Proc. Natl. Acad. Sci., U.S.A. 94: 9182–87.

21.

Buckley

C.D.

, Pilling

, Henriquez

N.V.

1999. RGD peptides induce apoptosis by direct caspase-3 activation. Nature, 397: 534–9.

22.

Burgeson

R.E.

, and Christiano

A.M.

1997. The dermal-epidermal junction. Curr. Opin. Cell. Biol., 9: 651–8.

23.

Byzova

T.V.

, Goldman

C.K.

, and Pampori

2000. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell., 6: 851–60.

24.

Cardones

A.R.

, and Banez

L.L.

2006. VEGF inhibitors in cancer therapy. Curr. Pharm. Des., 12: 387–94.

25.

Cao

, Cai

, Li

2006. Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem. Biophys. Res. Commun., 351: 726–32.

26.

Carron

C.P.

, Meyer

D.M.

, Engleman

V.W.

2000. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J. Endocrinol., 165: 587–98.

27.

Carpenter

A.E.

, and Sabatini

D.M.

2004. Systematic genome-wide screens of gene function. Nature Rev. Genet., 5: 11–22.

28.

Chan

B.M.

, Kassner

P.D.

, Schiro

J.A.

1992. Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. Cell., 68: 1051–60.

29.

Chow

T.W.

, Hellums

J.D.

, Moake

J.L.

1992. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood, 80: 113–20.

30.

Cresswell

, Wong

W.K.

, Henry

M.J.

2002. Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin. Cancer Immunol. Immunother., 51: 483–91.

31.

Chung

K.H.

, Kim

S.H.

, Han

K.Y.

2003. Inhibitory effect of salmosin, a Korean snake venom-derived disintegrin, on the integrin alphaV-mediated proliferation of SK-Mel-2 human melanoma cells. J. Pharm. Pharmacol., 55: 1577–82.

32.

Chung

, and Mercurio

A.M.

2004. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol. Cells, 17: 203–9.

33.

Coller

B.S.

2001. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb. Haemost, 86: 427–43.

34.

Colombatti

, Bonaldo

, and Doliana

1993. Type A modules: interacting domains found in several non-fibrillar collagens and in other extracellular matrix proteins. Matrix, 13: 297–306.

35.

Conway

E.E.

Jr 1993. Central nervous system findings and intussusception: how are they related? Pediatr. Emerg. Care., 9: 15–8.

36.

Cruz-Monserrate

, Qiu

, Evers

B.M.

2007. Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod. Pathol., 20: 656–67.

37.

Dangerfield

, Larbi

K.Y.

, Huang

M.T.

2002. PECAM-1 (CD31) homophilic interaction up-regulates alpha6beta1 on transmigrated neutrophils in vivo and plays a functional role in the ability of alpha6 integrins to mediate leukocyte migration through the perivascular basement membrane. J. Exp. Med., 196: 1201–11.

38.

Davidson

B.L.

, and Paulson

H.L.

2004. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol., 3: 145–9.

39.

Davis

G.E.

1992. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun., 182: 1025–31.

40.

Davis

T.L.

, Cress

A.E.

, Dalkin

B.L.

2001. Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate, 46: 240–8.

41.

de Fougerolles

A.R.

, and Springer

T.A.

1992. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J. Exp. Med., 175: 185–90.

42.

Dechantsreiter

M.A.

, Planker

, Matha

1999. N-methylated cyclic RGD peptides as highly active and selective a(V)h(3) integrin antagonists. J. Med. Chem., 42: 3033–40.

43.

Della Morte

, Squillacioti

, Garbi

2000. Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells. Eur. J. Biochem., 267: 5047–54.

44.

Demetriou

M.C.

, Pennington

M.E.

, Nagle

R.B.

2004. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp. Cell. Res., 294: 550–8.

45.

Dittmer

, Vetter

, Schunke

2006. Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J. Biol. Chem., 281: 14563–72.

46.

Duque

, LaRocco

, Golde

W.T.

2004. Interactions of foot-and-mouth disease virus with soluble bovine alpha v beta 3 and alphav beta 6 integrins. J. Virol., 78: 9773–81.

47.

Elbashir

S.M.

, Harborth

, and Weber

2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods, 26: 199–213.

48.

Eliceiri

B.P.

, Klemke

, Stromblad

1998. Integrin alphaV-beta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. Journal of Cellular Biology, 140: 1255–63.

49.

Eliceiri

B.P.

2001. Integrin and growth factor receptor crosstalk. Circ. Res., 89: 1104–10.

50.

Enserink

J.M.

, Methi

, Mahic

2004. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J. Biol. Chem., 279: 44889–96.

51.

Erdreich-Epstein

, Shimada

, Groshen

2000. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res., 60: 712–21.

52.

Falcioni

, Antonini

, Nistico

1997. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp. Cell. Res., 236: 76–85.

53.

Felding-Habermann

, Fransvea

, O'Toole

T.E.

2002. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis, 19: 427–36.

54.

Ferrer

F.A.

, Miller

L.J.

, Andrawis

R.I.

1998. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 51: 161–7.

55.

Ferrer

F.A.

, Miller

L.J.

, Lindquist

1999. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology, 54: 567–72.

56.

Folgiero

, Bachelder

R.E.

, Bon

2007. The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res., 67: 1645–52.

57.

Francis

S.E.

, Goh

K.L.

, Hodivala-Dilke

2002. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arteriosclerosis Thrombosis and Vascular Biology, 22: 927–33.

58.

Frieser

, Hallmann

, Johansson

1996. Mouse polymorphonuclear granulocyte binding to extracellular matrix molecules involves beta 1 integrins. Eur. J. Immunol., 26: 3127–36.

59.

W.M.

, Chang

T.K.

, Sun

W.Z.

2004. Inhibition of neuropathic pain by a potent disintegrin—triflavin. Neurosci Lett., 368: 263–8.

60.

Fujiwara

, Kikkawa

, Sanzen

2001. Purification and characterization of human laminin-8. Laminin-8 stimulates cell adhesion and migration through alpha3beta1 and alpha6beta1 integrins. J. Biol. Chem., 276: 17550–8.

61.

Galliher

A.J.

, and Schiemann

W.P.

2006. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res., 8: R.42.

62.

Ganju

, and Hall

2004. Potential applications of siRNA for pain therapy. Expert Opin. Biol. Ther., 4: 531–42.

63.

Gardner

J.M.

, and Hynes

R.O.

1985. Interaction of fibronectin with its receptor on platelets. Cell., 42: 439–48.

64.

Gettner

S.N.

, Kenyon

, and Reichardt

L.F.

1995. Characterization of beta pat-3 heterodimers, a family of essential integrin receptors in C. elegans. J. Cell. Biol., 129: 1127–41.

65.

Giancotti

F.G.

, and Ruoslahti

1999. Integrin signaling. Science, 285: 1028–32.

66.

Giannelli

, Sgarra

, Di Naro

2007. Endometriosis is characterized by an impaired localization of laminin-5 and alpha3beta1 integrin receptor. Int. J. Gynecol. Cancer, 17: 242–7.

67.

Gladson

C.L.

, Hancock

, Arnold

M.M.

1996. Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Am. J. Pathol., 148: 1423–34.

68.

Golubkov

, Hawes

, and Markland

F.S.

2003. Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis, 6: 213–24.

69.

Gould

R.J.

, Polokoff

M.A.

, Friedman

P.A.

1990. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med., 195: 168–71.

70.

Gramoun

, Shorey

, Bashutski

J.D.

2007. Effects of Vitaxin(R), a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J. Cell. Biochem., 102: 341–52.

71.

Green

P.M.

, Ludbrook

S.B.

, Miller

D.D.

2001. Structural elements of the osteopontin SVVYGLR. motif important for the interaction with alpha(4) integrins. FEBS Lett., 503: 75–9.

72.

Grzesiak

J.J.

, and Bouvet

2007. Determination of the ligand-binding specificities of the alpha2beta1 and alpha1beta1 integrins in a novel 3-dimensional in vitro model of pancreatic cancer Pancreas. 34: 220–8.

73.

Gullberg

, Velling

, Sjoberg

1995. Up-regulation of a novel integrin alpha-chain (alpha mt) on human fetal myotubes. Dev. Dyn., 204: 57–65.

74.

Guo

, and Giancotti

F.G.

2004. Integrin signalling during tumor progression. Nat. Rev. Mol. Cell. Biol., 5: 816–26.

75.

Guo

H.B.

, Lee

, Bryan

B.T.

2005. Deletion of mouse embryo fibroblast N. acetylglucosaminyltransferase V stimulates alpha5beta1 integrin expression mediated by the protein kinase C signaling pathway. J. Biol. Chem., 280: 8332–42.

76.

Guo

, Pylayeva

, Pepe

2006. β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell., 126: 489–502.

77.

Gutheil

J.C.

, Campbell

T.N.

, Pierce

P.R.

2000. Targeted antiangiogenic therapy for cancer using vitaxin: A humanized monoclonal antibody to the integrin αVβ3. Clinical Cancer Research, 6: 3056–61.

78.

Haier

, Goldmann

, Hotz

2002. Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastasis, 19: 665–72.

79.

Hallahan

D.E.

, Qu

, Geng

2001. Radiation-mediated control of drug delivery. Am. J. Clin. Oncol., 24: 473–80.

80.

Harms

J.F.

, Welch

D.R.

, Samant

R.S.

2004. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis, 21: 119–28.

81.

Haubner

, Kuhnast

, Mang

2004. [18F]Galacto-RGD: synthesis, radiolabelling, metabolic stability and radiation dose estimates. Bioconjug. Chem., 15: 61–9.

82.

Haubner

, Wester

H.J.

, Weber

W.A.

2001. Noninvasive imaging of vβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 61: 1781–5.

83.

Hedin

, Roy

, and Tran

P.K.

2004. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol., 15: 559–65.

84.

Heino

2000. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol., 19: 319–23.

85.

Herold-Mende

, Kartenbeck

, Tomakidi

2001. Metastatic growth of squamous cell carcinomas is correlated with upregulation and redistribution of hemidesmosomal components. Cell. Tissue. Res., 306: 399–408.

86.

Hirsch

, Iglesias

, Potocnik

A.J.

1996. Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Nature, 380: 171–5.

87.

Hollenbeck

, Itoh

, Louie

2004. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the alpha2beta1 integrin and PDGF beta receptor. Biochem. Biophys. Res. Commun., 325: 328–37.

88.

Huang

, Wu

, Zhu

1998. Expression of the human integrin beta6 subunit in alveolar type II cells and bronchiolar epithelial cells reverses lung inflammation in beta6 knockout mice. Am. J. Respir. Cell. Mol. Biol., 19: 636–42.

89.

Humphries

M.J.

2000. Integrin structure. Biochem. Soc. Trans., 28: 311–39.

90.

Hsia

D.A.

, Lim

S.T.

, Bernard-Trifilo

J.A.

2005. Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src. Mol. Cell. Biol., 25: 9700–12.

91.

Hynes

R.O.

2002. Integrins: bidirectional, allosteric signaling machines. Cell., 110: 673–87.

92.

Ishii

, Ochiai

, Yamada

2000. Integrin alpha6beta4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer. Gastroenterology, 118: 497–506.

93.

Jackson

, Clark

, Berryman

2004. Integrin {alpha}v{beta}8 Functions as a Receptor for Foot-and-Mouth Disease Virus: Role of the {beta}-Chain Cytodomain in Integrin-Mediated Infection. J. Virol., 78: 4533–40.

94.

Jackson

, Mould

A.P.

, Sheppard

2002. Integrin alpha v beta1 is a receptor for foot-and-mouth disease virus. J. Virol., 76: 935–41.

95.

Jackson

, Sharma

, Ghazaleh

R.A.

1997. Arginineglycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the purified integrin alpha v beta 3 in vitro. J. Virol., 71: 8357–61.

96.

Jackson

, Sheppard

, Denyer

, Blakemore

, and King

A.M.

2000. The epithelial integrin alpha v beta 6 is a receptor for foot-and-mouth disease virus. J. Virol., 74: 4949–56.

97.

Jan

, Matter

, Pai

J.T.

2004. A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell., 116: 751–62.

98.

, Thomas

K.S.

, Wu

2003. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J. Biol. Chem., 278: 46692–8.

99.

Jodele

, Chantrain

C.F.

, Blavier

2005. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res., 65: 3200–8.

100.

Jones

, Watt

F.M.

, and Speight

P.M.

1997. Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J. Oral Pathol. Med., 26: 63–8.

101.

Joshi

, Chung

C.Y.

, Aukhil

1993. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J. Cell. Sci., 106: 389–400.

102.

Kallio

J.P.

, Mikkelsson

, Tammela

T.L.

2006. Genetic variation in platelet integrin alpha IIb beta 3 (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma. BJU Int., 9: 201–4.

103.

Kang

I.C.

, Lee

Y.D.

, and Kim

D.S.

1999. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res., 59: 3754–60.

104.

Karczewski

, Knudsen

K.A.

, and Smith

1989. The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. J. Biol. Chem., 264: 21322–6.

105.

Karadag

, Ogbureke

K.U.

, Fedarko

N.S.

2004. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst., 96: 956–65.

106.

Kennel

S.J.

, Foote

L.J.

, Falcioni

1989. Analysis of the tumor-associated antigen TSP-180. Identity with α6β4 in the integrin superfamily. J. Biol. Chem., 264: 15515–21.

107.

Kerr

J.S.

, Slee

A.M.

, and Mousa

S.A.

2002. The alpha V integrin antagonists as novel anticancer agents: an update. Expert Opin. Investig. Drugs, 11: 1765–74.

108.

Kim

, Bell

, Mousa

S.A.

2000. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. American Journal of Pathology, 156: 1345–62.

109.

Kimura

, Toyoshima

, Kojima

1998. Entactin-2: a new member of basement membrane protein with high homology to entactin/nidogen. Exp. Cell. Res., 241: 36–45.

110.

Kippenberger

, Loitsch

, Muller

2004. Ligation of the beta4 integrin triggers adhesion behavior of human keratinocytes by an “inside-out” mechanism. J. Invest. Dermatol., 123: 444–51.

111.

Kloczewiak

, Timmons

, and Bednarek

M.A.

1989. Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. Biochemistry, 28: 2915–9.

112.

Kramer

R.H.

, Vu

M.P.

, Cheng

Y.F.

1991. Laminin-binding integrin alpha 7 beta 1: functional characterization and expression in normal and malignant melanocytes. Cell. Regul., 2: 805–17.

113.

Kumar

C.C.

2003. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug. Targets, 4: 123–31.

114.

Kumar

C.C.

, Malkowski

, Yin

2001. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res., 61: 2232–8.

115.

Kuwada

S.K.

, Kuang

, and Li

2005. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. J. Biol. Chem., 280: 19027–35.

116.

Lee

J.W.

, and Juliano

R.L.

2000. Alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol. Biol. Cell., 11: 1973–87.

117.

, Redick

S.D.

, Erickson

H.P.

2003. Force measurements of the alpha5beta1 integrin-fibronectin interaction. Biophys. J., 84: 1252–62.

118.

, Tan

, Dong

2007. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig. Liver Dis., 39: 557–65.

119.

Lipscomb

E.A.

, Dugan

A.S.

, Rabinovitz

2003. Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin. Exp. Metastasis, 20: 569–76.

120.

Lipscomb

E.A.

, Simpson

K.J.

, Lyle

S.R.

2005. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res., 65: 10970–6.

121.

Liu

, Ordonez-Ercan

, Fan

2007. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer, 120: 874–82.

122.

Lopez-Conejo

M.T.

, Olmo

, Turnay

2002. Interaction of fibronectin with human colon adenocarcinoma cells: effect on the in vivo tumorigenic capacity. Oncology, 62: 371–80.

123.

Lopez

M.A.

, Mayer

, Hwang

2005. Force transmission, compliance, and viscoelasticity are altered in the alpha7-integrin-null mouse diaphragm. Am. J. Physiol. Cell. Physiol., 288: C282–9.

124.

Maglott

, Bartik

, Cosgun

2006. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res., 66: 6002–7.

125.

Marinelli

, Meyer

, Heckmann

2005. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem., 48: 4204–7.

126.

Markland

F.S.

, Shieh

, Zhou

2001. A novel snake venom disintegrin that inhibits human varian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis, 31: 183–91.

127.

Marlin

S.D.

, and Springer

T.A.

1987. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell., 51: 813–9.

128.

Marcinkiewicz

, Weinreb

P.H.

, Calvete

J.J.

2003. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res., 63: 2020–3.

129.

Martin

P.L.

, Jiao

, Cornacoff

2005. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alpha V integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer. Res., 11: 6959–65.

130.

Maubant

, Saint-Dizier

, Boutillon

2006. Blockade of alpha V beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood, 108: 3035–44.

131.

McCabe

N.P.

, De

, Vasanji

2007. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene, 26: 6238–43.

132.

McHugh

K.P.

, Hodivala-Dilke

, Zheng

M.H.

2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest, 105: 433–40.

133.

McLane

M.A.

, Sanchez

E.E.

, Wong

2004. Disintegrins. Curr. Drug Targets Cardiovasc. Haematol. Disord., 4: 327–55.

134.

McNeel

D.G.

, Eickhoff

, Lee

F.T.

2005. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res., 11: 7851–60.

135.

McQuade

, and Knight

L.C.

2003. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3. Q. J. Nucl. Med., 47: 209–20.

136.

McQuade

, Knight

L.C.

, and Welch

M.J.

2004. Evaluation of 64Cu-and 125I-radiolabeled bitistatin as potential agents for targeting alphavbeta3 integrins in tumor angiogenesis. Bioconjug Chem., 15: 988–96.

137.

Meerovitch

, Bergeron

, Leblond

2003. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul Pharmacol., 40: 77–89.

138.

Mercurio

A.M.

, Rabinovitz

, and Shaw

L.M.

2001. The alpha 6 beta 4 integrin and epithelial cell migration. Curr. Opin. Cell. Biol., 13: 541–5.

139.

Minagar

, Sheremata

W.A.

, Vollmer

T.L.

2000. Reduction of relapses in multiple sclerosis after anti-alpha4 integrin antibody (natalizumab). International Journal of MS Care, 3: 1–6. Available at http://www.mscare.com.

140.

Mitjans

, Meyer

, Fittschen

2000. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int. J. Cancer, 87: 716–23.

141.

Mitjans

, Sander

, Adan

1995. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J. Cell. Sci., 108: 2825–38.

142.

Miyata

, Koshikawa

, Yasumitsu

2000. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J. Biol. Chem., 275: 4592–8.

143.

Mousa

S.A.

2002. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol., 6: 534–41.

144.

, Cambier

, Fjellbirkeland

2002. The integrin alpha v beta 8 mediates epithelial homeostasis through MT1-MMPdependent activation of TGF-beta1. J. Cell. Biol., 157: 493–507.

145.

Muchowski

P.J.

, Zhang

, Chang

E.R.

1994. Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18. J. Biol. Chem., 269: 26419–23.

146.

Mullamitha

S.A.

, Ton

N.C.

, Parker

G.J.

2007. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res., 13: 2128–35.

147.

Munger

J.S.

, Huang

, Kawakatsu

1999. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell., 96: 319–28.

148.

Murillo

C.A.

, Rychahou

P.G.

, and Evers

B.M.

2004. Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery, 136: 143–9.

149.

Niewiarowski

, McLane

M.A.

, Kloczewiak

1994. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin. Hematol., 31: 289–300.

150.

O'Connor

, Goodman

, Willmer-Hulme

A.J.

2004. Randomized multicentre trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology, 62: 2038–43.

151.

O'Connor

, Miller

, Riester

2005. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Multiple Sclerosis, 11: 568–72.

152.

Paddison

P.J.

, and Hannon

G.J.

2003. siRNAs and shRNAs: skeleton keys to the human genome. Curr. Opin. Mol. Ther., 5: 217–22.

153.

Parise

L.V.

, Lee

, and Juliano

R.L.

2000. New aspects of integrin signaling in cancer. Semin. Cancer Biol., 10: 407–14.

154.

Paulhe

, Racaud-Sultan

, Ragab

2001. Differential regulation of phosphoinositide metabolism by alphaVbeta3 and alphaVbeta5 integrins upon smooth muscle cell migration. J. Biol. Chem., 276: 41832–40.

155.

Pawar

S.C.

, Demetriou

M.C.

, Nagle

R.B.

2007. Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp. Cell. Res., 313: 1080–9.

156.

Perlino

, Lovecchio

, Vacca

R.A.

2000. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am. J. Pathol., 157: 1727–34.

157.

Popova

S.N.

, Barczyk

, Tiger

C.F.

2007. {alpha}11{beta}1 Integrin-Dependent Regulation of Periodontal Ligament Function in the Erupting Mouse Incisor. Mol. Cell. Biol., 27: 4306–16.

158.

Pytela

, Pierschbacher

M.D.

, and Ruoslahti

1985. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginineglycine-aspartic acid adhesion sequence derived from fibronectin. Proc. Natl. Acad. Sci., U.S.A. 82: 5766–70.

159.

Rahimi

, Hung

, Tremblay

1998. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem., 273: 33714–21.

160.

Ramakrishnan

, Bhaskar

, Law

D.A.

2006. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol., 5: 273–86.

161.

Ramos

D.M.

, But

, Regezi

2002. Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol., 21: 297–307.

162.

Reinmuth

, Liu

, Ahmad

S.A.

2003. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res., 63: 2079–87.

163.

Reynolds

A.R.

, Reynolds

L.E.

, Nagel

T.E.

2004. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Research, 64: 8643–50.

164.

Rhodes

2005. Developing a cell line standard for HER2/neu. Cancer Biomark, 1: 229–32.

165.

Risau

1997. Mechanisms of angiogenesis. Nature, 386: 671–4.

166.

Rodier

J.M.

, Valles

, and Denoyelle

1995. pp60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. J. Cell. Biol., 131: 761–73.

167.

Ruegg

, and Mariotti

2003. Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cellular and Molecular Life Sciences, 60: 1135–57.

168.

Ruggeri

Z.M.

, De Marco

, and Gatti

1983. Platelets have more than one binding site for von Willebrand factor. J. Clin. Invest., 72: 1–12.

169.

Sabherwal

, Rothman

V.L.

, Dimitrov

2006. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell. Res., 312: 2443–53.

170.

Sakai

, Zhang

, Fassler

1998. Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain. J. Cell. Biol., 141: 527–38.

171.

Scarborough

R.M.

, Kleiman

N.S.

, and Phillips

D.R.

1999. Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, 100: 437–44.

172.

Schnapp

L.M.

, Breuss

J.M.

, Ramos

D.M.

1995. Sequence and tissue distribution of the human integrin alpha 8 subunit: a beta 1-associated alpha subunit expressed in smooth muscle cells. J. Cell. Sci., 108: 537–44.

173.

Shen

, and Falzon

2006. PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells. Exp. Cell. Res., 312: 3822–34.

174.

Shen

, Mula

R.V.

, Evers

B.M.

2007. Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines. Regul. Pept., 141: 61–72.

175.

Senger

D.R.

, Perruzzi

C.A.

, Streit

2002. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol., 160: 195–204.

176.

Shaw

L.M.

2001. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol. Cell. Biol., 21: 5082–93.

177.

Sheu

J.R.

, Wu

C.H.

, Chen

Y.C.

2001. Mechanisms in the inhibition of neointimal hyperplasia with triflavin in a rat model of balloon angioplasty. J. Lab. Clin. Med., 137: 270–8.

178.

Shimaoka

, and Springer

T.A.

2004. Therapeutic antagonists and the conformational regulation of the beta2 integrins. Curr. Top. Med. Chem., 4: 1485–95.

179.

Silvestre

J.S.

, Thery

, Hamard

2005. Lactadherin promotes VEGF-dependent neovascularization. Nature Medicine, 11: 499–506.

180.

Song

, Lee

S.K.

, Wang

2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med., 9: 347–51.

181.

Stroeken

P.J.

, van Rijthoven

E.A.

, Boer

2000. Cytoplasmic domain mutants of beta1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis. Oncogene, 19: 1232–8.

182.

Sabherwal

, Rothman

V.L.

, Dimitrov

2006. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell. Res., 312: 2443–53.

183.

Sudhakar

, Nyberg

, Keshamouni

V.G.

2005. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J. Clin. Invest., 115: 2801–10.

184.

Swenson

, Costa

, Minea

2004. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol. Cancer. Ther., 3: 499–511.

185.

Taga

, Suzuki

, Gonzalez-Gomez

2002. Alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer., 98: 690–7.

186.

Tanaka

, Mimori

, Shiraishi

2000. Alpha6 integrin expression in esophageal carcinoma. Int. J. Oncol., 16: 725–9.

187.

Takanami

2005. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer, 5: 1–7.

188.

Taylor

M.R.

, Couto

J.R.

, Scallan

C.D.

1997. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell. Biol., 16: 861–9.

189.

Thomas

G.J.

, Lewis

M.P.

, Hart

I.R.

2000. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer, 92: 641–50.

190.

Thomas

G.J.

, Nystrom

M.L.

, and Marshall

J.F.

2006. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J. Oral. Pathol. Med., 35: 1–10.

191.

Thomas

G.J.

, Poomsawat

, Lewis

M.P.

2001. Alphavbeta6 integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J. Invest Dermatol., 116: 898–904.

192.

Tiger

C.F.

, Fougerousse

, Grundstrom

2001. Alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. Dev. Biol., 237: 116–29.

193.

Travis

M.A.

, Humphries

J.D.

, and Humphries

M.J.

2003. An unraveling tale of how integrins are activated from within. Trends. Pharmacol. Sci., 24: 192–7.

194.

Trikha

, Timar

, Zacharek

2002a. Role for beta3 integrins in human melanoma growth and survival. Int. J. Cancer, 101: 156–67.

195.

Trikha

, Zhou

, Timar

2002b. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res., 62: 2824–33.

196.

Trikha

, Zhou

, Nemeth

J.A.

2004. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer., 110: 326–35.

197.

Tsuji

2004. Physiological and pathological roles of alpha3beta1 integrin. J. Memb. Biol., 200: 115–32.

198.

Tsuji

, Kawada

, Kai-Murozono

2002. Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin. Exp. Metastasis, 19: 127–34.

199.

Tucker

G.C.

2003. Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig Drugs, 4: 722–31.

200.

Tulla

, Pentikainen

O.T.

, Viitasalo

2001. Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, and alpha 10I domains. J. Biol. Chem., 276: 48206–12.

201.

Venter

J.C.

, Adams

M.D.

, Myers

E.W.

2001. The sequence of the human genome. Science, 291: 1304–51.

202.

Weaver

V.M.

, Lelievre

, Lakins

J.N.

2002. Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell., 2: 205–16.

203.

Wei

, Tang

C.H.

, Kim

2007. Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem., 282: 3929–39.

204.

Weinacker

, Ferrando

, Elliott

1995. Distribution of integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and tenascin, in human airways. Am. J. Respir. Cell. Mol. Biol., 12: 547–56.

205.

Weinreb

P.H.

, Simon

K.J.

, Rayhorn

2004. Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligandmimetic and nonligand-mimetic classes. J. Biol. Chem., 279: 17875–87.

206.

White

D.E.

, Kurpios

N.A.

, Zuo

2004. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell., 6: 159–70.

207.

Wick

, Naumann

, and Weller

2006. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des., 12: 341–9.

208.

Woska

J.R.

Jr , Morelock

M.M.

, Jeanfavre

D.D.

1996. Characterization of molecular interactions between intercellular adhesion molecule-1 and leukocyte function- associated antigen-1. J. Immunol., 156: 4680–5.

209.

Wright

S.D.

, and Silverstein

S.C.

1983. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J. Exp. Med., 158: 2016–23.

210.

W.B.

, Peng

H.C.

, and Huang

T.F.

2003. Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell-cell and cell-ECM interactions in regulating cell viability. Exp. Cell. Res., 286: 115–27.

211.

Xiong

J.P.

, Stehle

, Diefenbach

2001. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science, 294: 339–45.

212.

Xiong

J.P.

, Stehle

, Goodman

S.L.

2004. A novel adaptation of the integrin PSI domain revealed from its crystal structure. J. Biol. Chem., 279: 40252–4.

213.

Xiong

J.P.

, Stehle

, Zhang

2002. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 296: 151–5.

214.

Yang

, Zeisberg

, Lively

J.C.

2003. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res., 63: 8312–7.

215.

Yao

E.S.

, Zhang

, Chen

Y.Y.

2007. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res., 67: 659–64.

216.

Yeh

C.H.

, Peng

H.C.

, and Huang

T.F.

1998. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alpha V beta 3 antagonist and inducing apoptosis. Blood, 92: 3268–76.

217.

Zhang

, Pier

, McNeel

D.G.

, Wilding

2007. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels—a pharmacodynamic study. Invest. New Drugs, 25: 49–55.

218.

Zhang

, and Plow

E.F.

1996. A discrete site modulates activation of I domains. Application to integrin alphaMbeta2. J. Biol. Chem., 271: 29953–7.

219.

Zheng

D.Q.

, Woodard

A.S.

, Fornaro

1999. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res., 59: 1655–64.

220.

Zheng

D.Q.

, Woodard

A.S.

, Tallini

2000. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J. Biol. Chem., 275: 24565–74.

221.

Zhou

, Murphy

F.R.

, Gehdu

2004. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem., 279: 23996–4006.

222.

Zhou

, Nakada

M.T.

, Arnold

1999. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis, 3: 259–69.

223.

Ziober

B.L.

, Chen

Y.Q.

, Ramos

D.M.

1999. Expression of the alpha7beta1 laminin receptor suppresses melanoma growth and metastatic potential. Cell. Growth Differ., 10: 479–90.

224.

Zutter

M.M.

, Santoro

S.A.

, Staatz

W.D.

1995. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci., U.S.A. 92: 7411–5.

The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy

Abstract

Keywords

Introduction

Integrin Family

Integrin Structure

Integrin and Cancer

β1 class of integrins

αV class of integrin

Other sub-classes of integrins

Integrins as Targets for the Treatment of Cancer

Antibodies against Integrins as Inhibitors

MEDI-552

CNTO 95

17E6

Other antibodies

Disintegrins, RGD-Based Peptides and Small Molecule Integrin Antagonists

Conclusions

Footnotes

References

β₁ class of integrins

α_V class of integrin